Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Multilayer brain connectivity and long-term cognitive changes in individuals at risk for Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

White matter hyperintensities in Alzheimer's disease in the era of anti-amyloid therapies.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Iatrogenic Cerebral Amyloid Angiopathy After Cardiac Surgery: Two Case Reports.

Neurology·2026
Same author

Author Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a β Test.

Neurology·2026
Same author

Reader Response: Alzheimer Disease Is a Specific Disorder Defined by Neuropathology Detectable During Life.

Neurology·2026
Same author

Defining Alzheimer's disease: stipulations and the ethics of diagnostic change.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Nicolas Villain1

  • 1Assistance Publique Hopitaux de Paris (APHP), Paris, France.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

国际工作组 (IWG) 框架区分高风险的认知正常个体 ("症状前阿尔茨海默病") 和低风险的个体 ("无症状风险"). 这种分层对于推动生物标志物研究和开发针对性阿尔茨海默氏症治疗方法至关重要.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物 生物标志物
  • 神经退行性疾病 神经退行性疾病

背景情况:

  • 国际工作组 (IWG) 框架将认知能力不受损害,生物标志物阳性个体分为"症状前阿尔茨海默病" (AD) 或"无症状风险".
  • 这与阿尔茨海默氏症协会 (AA) 的标准形成鲜明对比,该协会将两者归类为"临床前AD".
  • 在AD研究中,IWG分层强调临床风险,而不是纯粹的病理生理连续性.

研究的目的:

  • 审查和综合IWG和AA框架上的发现,用于对具有AD生物标志物的认知正常个体进行分类.
  • 突出IWG框架对于理解临床和生物标志物轨迹的重要性.
  • 强调IWG框架在指导针对认知正常人群量身定制的药理学开发方面的重要性.

主要方法:

  • 文献综述综合了IWG和AA框架的发现.
  • 分析IWG框架对临床和生物标志物轨迹的影响.
  • 评估IWG框架在量身定制的药理开发中的作用.

主要成果:

  • 在认知上正常,生物标志物阳性个体在进展风险上表现出显著的异质性.
  • 孤立的粉样蛋白阳性表明风险低 (5-31%),而联合粉样蛋白和新皮质病理表明风险高.
  • IWG的分类有助于生物标志物研究,通过将个人资料与不同的临床轨迹对齐,并通过量身定制风险/益处比率来优化药物开发.

结论:

  • 该IWG框架有效地将生物标志物研究和临床结果与临床前阿尔茨海默病的临床结合起来.
  • 区分"无症状风险"和"预症状AD"促进生物标志物创新,完善风险分层,并促进个性化治疗策略.
  • 该框架支持EuroPAD社区针对个性化干预的目标,并使研究与临床和公共卫生需求保持一致.